Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||INCB054329 + Pemigatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|INCB054329||INCB-054329||BET Inhibitor (Pan) 27||INCB054329 is BET inhibitor, which results in decreased expression of BET protein-regulated genes including MYC, potentially leading to decreased tumor cell proliferation (PMID: 30206163)|
|Pemigatinib||Pemazyre||INCB54828|INCB054828||FGFR1 Inhibitor 23 FGFR2 Inhibitor 15 FGFR3 Inhibitor 13||Pemazyre (pemigatinib) is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR1/2/3 signaling, which results in growth inhibition in tumor cells (PMID: 32203698). Pemazyre (pemigatinib) is FDA approved for use in patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||INCB054329 + Pemigatinib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with the combination of INCB054329 and Pemazyre (pemigatinib) decreased MYC expression and FGFR3 signaling and inhibited tumor growth in a t(4;14)-positive myeloma cell line xenograft model, demonstrating increased efficacy over either agent alone (PMID: 30206163).||30206163|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|